Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain ABT Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.

BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls

by Zacks Equity Research

Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.

Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Is Insulet Stock a Smart Addition to Your Portfolio Right Now?

by Zacks Equity Research

PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.

Cencora Rallies 14.7% Year to Date: What's Driving the Stock?

by Zacks Equity Research

COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.

BAX or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BAX vs. LMAT: Which Stock Is the Better Value Option?

Should Value Investors Buy Baxter International (BAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

by Zacks Equity Research

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Catalent Stock Flat Following the Sell Agreement With Ardena

by Zacks Equity Research

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

HealthEquity Gains 28.3% YTD: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Reasons to Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's strong product demand and continued focus on R&D raise optimism about the stock.

SNN Stock May Gain Following the Co-Marketing Deal With JointVue

by Zacks Equity Research

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research

by Zacks Equity Research

BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.

SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

by Zacks Equity Research

SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

by Zacks Equity Research

AMN Healthcare aims to enhance staffing efficiency and improve operational efficiency in healthcare systems via the latest launch.

Here's Why You Should Add DaVita Stock to Your Portfolio Now

by Zacks Equity Research

DVA's strength in its kidney care business raises optimism about the stock.

Here's Why You Should Add Masimo Stock to Your Portfolio Now

by Zacks Equity Research

MASI's R&D activities raise optimism about the stock.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

by Zacks Equity Research

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Reasons to Add Baxter International Stock to Your Portfolio Now

by Zacks Equity Research

BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Here's Why You Should Retain Merit Medical Stock in Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Here's Why Baxter International (BAX) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

by Zacks Equity Research

Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.

Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?

by Zacks Equity Research

Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.